AbbVie Inc. (ABBV) on Friday said the European Commission has approved Skyrizi for the treatment of adults with ulcerative colitis.
Ulcerative colitis is a type of inflammatory bowel disease (IBD) causing inflammation on the lining of the large intestine and rectum.
The approval was based on two phase studies, INSPIRE induction trial and COMMAND maintenance trial, in which Skyrizi achieved the primary endpoint of clinical remission.
SKYRIZI is already approved in the U.S. to treat ulcerative colitis, Crohn's disease, plaque psoriasis, and psoriatic arthritis.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.